Ocular Therapeutix™ To Report Third Quarter 2023 Financial Results
24 Outubro 2023 - 9:00AM
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical
company focused on the formulation, development, and
commercialization of innovative therapies for diseases and
conditions of the eye, today announced that it will report third
quarter ended September 30, 2023 financial results after the close
on Tuesday, November 7, 2023. Following distribution of the
earnings release via wire services, the Ocular Therapeutix
management team will host a live conference call and webcast
at 4:30 p.m. Eastern Time to review the Company’s financial
results and provide a general business update.
Listeners can register for the webcast via this link. Those who
plan on participating are advised to join 15 minutes prior to the
start time. Analysts wishing to participate in the question and
answer session should use this link. A replay of the webcast will
be available via the Company’s investor website approximately two
hours after the call’s conclusion for 90 days.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company
focused on the formulation, development and commercialization of
innovative therapies for diseases and conditions of the eye using
its proprietary bioresorbable hydrogel-based formulation technology
ELUTYX™. Ocular Therapeutix’s first commercial drug product,
DEXTENZA®, is an FDA-approved corticosteroid for the treatment of
ocular inflammation and pain following ophthalmic surgery and
ocular itching associated with allergic conjunctivitis. Ocular
Therapeutix’s earlier stage development assets include: OTX-TKI
(axitinib intravitreal implant), currently in a pivotal Phase 3
trial for wet AMD and a Phase 1 clinical trial for the treatment of
diabetic retinopathy; OTX-TIC (travoprost intracameral implant),
currently in a Phase 2 clinical trial for the treatment of primary
open-angle glaucoma or ocular hypertension; and OTX-CSI
(cyclosporine intracanalicular insert) for the chronic treatment of
dry eye disease and OTX-DED (dexamethasone intracanalicular insert)
for the short-term treatment of the signs and symptoms of dry eye
disease, both of which have completed Phase 2 clinical trials.
InvestorsOcular TherapeutixDonald NotmanChief
Financial Officerdnotman@ocutx.comorICR WestwickeChris Brinzey,
339-970-2843Managing Directorchris.brinzey@westwicke.com
MediaICR WestwickeBen Shannon,
443-213-0495ben.shannon@westwicke.com
Ocular Therapeutix (NASDAQ:OCUL)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Ocular Therapeutix (NASDAQ:OCUL)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024